🚨 New NEJM Study Alert! 🧬💊
Baxdrostat, a selective aldosterone synthase inhibitor, shows significant BP reduction in patients with resistant & uncontrolled hypertension despite RAAS blockade and diuretic therapy.
✅ SBP ↓ ~9–10 mmHg at 12 weeks
🧂 Targets salt-retaining physiology
⚖️ Well-tolerated: early mild hyperkalemia & hyponatremia
🔁 Durable effect even after withdrawal
A promising step toward precision therapy in tough-to-treat hypertension!
📖 Read more: NEJM Aug 2025 | BaxHTN Trial
#Hypertension #Cardiology #Baxdrostat #Aldosterone #RAAS #NEJM #PrecisionMedicine #ClinicalTrials
